CEEPC/IPM/CMSC - Abstrakt prezentace

(CEEPC/IPM/CMSC 2022 - FrO-08)
Synergistic success of proteo-genomics in profiling human tear fluid for disease biomarkers using a novel high sensitivity Immunoassay

Marianna Dor 1, Edina Kishazi 1, Suresh Jivan Gadher 2,3 *

  1. Faculté de médecine, Département de science des protéines humaines, CH - 1211 Genève 4
  2. Thermo Fisher Scientific, 5781 Van Allen Way, Carlsbad, CA 92008 USA
  3. Founder Member - CEEPC


Quest for key disease biomarker(s) is one of the biggest challenges of today. Human tears, with their comprehensive biomolecule repertoire, are a good source of biomarkers and offer an excellent opportunity for patient stratification in precision medicine. Tear fluid is a potential medium for biomarker discovery in ocular, metabolic and systemic diseases such as diabetic retinopathy, cystic fibrosis and cancers [1]. The proximity of the tear fluid to the brain, makes it an ideal fluid for studying neurological disorders such as multiple sclerosis, Parkinson’s disease and brain tumors. Tear collection is fast and noninvasive using a Schirmer's strip [2].

Researchers studying the multifaceted etiology of various diseases require powerful investigational tools with greater sensitivity, better dynamic range, miniscule micro-litre volume consumption and robust data analysis software. ProQuantum™ High Sensitivity Immunoassays incorporating analyte specificity of high affinity antibody-antigen binding with the signal detection and amplification of real-time PCR technologies, offers a flexible and scalable qPCR assay platform enabling multidimensional analysis of DNA, RNA, and now biological proteins. It can play an integral role in screening large number of tear samples for molecular signature of human diseases at protein level in eye clinics and for establishing biomarker profiles of disease status [3].

It is anticipated that an established ‘tear test’ would be a very powerful prognostic and / or diagnostic test in eye clinics in the near future for systemic, neuronal and ocular diseases. ProQuantum™ Immunoassay with its unique features, can benefit precision medicine by maximizing patient’s data outcome while minimizing potential health disparities.

* Korespondující autor: gadhersuresh@hotmail.com


  1. Kishazi E. et al.: Sci Rep 17; 8(1), 10792 (2018).
  2. Kishazi E. et al.: J Proteomics 170, 110-116 (2018).
  3. Dor M. et al.: Exp Eye Res 179, 64-74(2019).


This research was in collaboration with Faculté de médecine, Département de science des protéines humaines, CH - 1211 Genève 4 and Thermo Fisher Scientific, Carlsbad, CA 92008 USA.

Partneři společnosti

LabRules LCMS LabRules GCMS


Bruker HPST Merck Pragolab Amedis EastPort Shimadzu Waters